Cognitive science company Cogstate (ASX:CGS) has raised $2 million through a placement of shares to an entity controlled by Dr Alan Finkel, who has also being appointed a non-executive director of the company.
Finkel is a long time investor in the company with extensive experience running a neuroscience-based technology company in the U.S.
The funds were raised through a placement of 8 million shares priced at $0.25 each.
Cogstate expects to record positive EBITDA for the second half of financial year 2015, based on existing contracted revenue.
At the end of April, the updated total value of clinical trials contracts signed FYTD was US$21.9 million.
The company has forecast revenues of A$15.58 million from existing sales contracts for FY2015, a 46% growth on the previous year.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.78 |
Change
-0.040(2.20%) |
Mkt cap ! $302.2M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.83 | $1.78 | $205.3K | 113.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1097 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 9361 | 2 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |